Reviewing the amendment protocol of the AstraZeneca's fixed dose combination (FDC) Zibotentan plus Dapagliflozin, the Subject ...

AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises ...

Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.

Taking a statin medication is an effective, safe, and low-cost way to lower cholesterol and reduce risk of cardiovascular ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has published updated Final Draft Guidance recommending Forxiga (dapagliflozin) as an option to treat chronic ...

AstraZeneca PLC (NASDAQ:AZN), a pharmaceutical and biotech firm based in Cambridge, UK, reported positive results from its ...

The use of intermittent scanning continuous glucose monitoring improves glycaemic control outcomes in older adult patients ...

Taking a statin medication is an effective, safe, and low-cost way to lower cholesterol and reduce risk of cardiovascular events. Despite clinicians recommending that many patients with diabetes take ...

Aptar Digital Health has signed a licensing agreement with AstraZeneca for detecting CKD using the latter’s AI-driven ...

AstraZeneca will pay Bristol-Myers Squibb US $3.4 billion in cash, and the companies will share profits and losses. “Amylin’s innovative diabetes portfolio, talent people and state-of-the-art ...

GLP-1 receptor agonists may modestly reduce the risk for 14 obesity-related cancers, especially colorectal cancer, among ...